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1. Introduction 
Adriamycin is one of the most potent antitumor 
drugs and particularly effective against solid tumors 
and leukemias [l-3]. Its antitumor action has been 
attributed to intercalation between adjacent DNA 
basepairs [4] and to the thus-caused inhibitory effect 
on DNA replication, RNA- and protein synthesis 
[5,6]. Despite its very efficient inhibition of tumor 
growth, its clinical use has been limited by an asso- 
ciated, severe cardiotoxicity in form of a dose- 
dependent, progressive and mostly irreversible, often 
lethal cardiomyopathy [2,7-lo]. Ultrastructurally, 
degeneration of various cytoplasmic structures (myo- 
filaments, mitochondria, sarcoplasmic reticulum) and 
ultimately myocellular necrosis have been demon- 
strated both in humans and in several animal models 
and were held responsible for the development of the 
cardiomyopathy [7-9,111. 
Investigations on the adriamycin cardiomyopathy 
have presented evidence for an inhibitory effect of 
adriamycin on the myocardial DNA metabolism, in 
particular DNA-replication and DNA-repair mecha- 
nisms [ 12-141. Since the incorporation of radio- 
active amino acids into myocardial protein was 
impaired in adriamycin-treated animals [ 151, it was 
proposed that this reflects a reduced myocardial pro- 
tein synthesis rate as consequence of a more direct 
effect of adriamycin on DNA-replication and -expres- 
sion, and it was postulated that this could be respon- 
sible for the development of the adriamycin cardio- 
myopathy. 
We have shown [ 161 that cyclical treatment of rats 
with adriamycin leads to pronounced decreases in the 
myocardial content of polyribosomes. We have now 
extended this study to an analysis of the effect of 
adriamycin onto the myocardial mRNA content and 
the activity of the myocardial pH 5 enzymes. Both 
parameters are severely decreased in adriamycin- 
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treated rats, mRNA by 5 1.6%, the pH 5 enzymes by 
35%. The specific mRNA species coding for the 
individual myofibrillar proteins seem to be affected 
to a similar degree. 
2. Materials and methods 
Male Sprague-Dawley rats, 150 g body weight 
(b.w.), fed overnight, were injected with adriamycin 
intraperitoneally, 10 or 15 mg/kg b.w. (control 
groups received 0.9% NaCl). Each group consisted of 
1 O-l 5 rats. They were decapitated 7-14 days after 
injection of adriamycin. Hearts were pooled and poly- 
ribosomes and mRNA isolated as in [ 16,171. 
The mRNA was translated in vitro in the mRNA- 
dependent reticulocyte lysate system [ 181, the cell- 
free synthesized products were separated on a 10% 
polyacrylamide slab-gel [ 191 and visualized by fluo- 
rography [20]. 
Myocardial contents of DNA, RNA, protein and 
pH 5 enzymes were determined as in [21-241. 
3. Results and discussion 
The effect of adriamycin on animal survival rate, 
body weight, heart weight, and the myocardial con- 
tents of DNA, RNA and protein are illustrated in 
table 1. In accordance with [ 141, there is a close cor- 
relation between dose of adriamycin and survival rate, 
with -l/2 of the animals of the 10 mg/kg b.w. group 
dying within 14 days. In all subsequent experiments, 
adriamycin was thus given 7-14 days before decap- 
itation. Myocardial DNA and protein contents 
changed only little after adriamycin treatment 
(table l), myocardial total RNA and microsomal 
RNA somewhat more (table 1). 
In contrast, adriamycin caused a severe decrease in 
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Table 1 
Effect of adriamycin on animal survival rate, body wetght and heart weight, myocardial DNA, 
RNA and protein contents 
Controls Adriamycin 
January 1981 
10 mg/kg body wt 15 mg/kg body wt 
100% 
133 + 15.3 
176 f 23.4 ( 
0.55 + 0.06 
1.43 f 0.12 
2.05 f 0.18 
Ammal survival rate 
Body weight (g) 
initial weight 
end weight 











134 + 17.1 
137 + 23.6 
0.42 r 0.05 
1.31 f 0.13 
(6) 1.71 ? 0.17 
Wg heart) 703 k 70 (ll) 
Protein content 
(mgig heart) 171 f 27 (6) 
57% 229 
11) 133 f 16.5 
11) 130 f 36.2 
11) 0.40 r 0.09 
(6) 1.28 f 0.16 






625 f 113 (11) 616 + 108 (11) 
166 f 20 (6) 164 + 19 (5) 
Values are the mean f SEM (no. preps., each preparation containing 5-10 rats). Myocardial DNA, 
RNA and protein were determined essentially as in [ 16,21-23 ]. Adriamycin was injected as described 
in the text. Survival rates refer to the no. animals surviving 14 days after application of adriamycin 
(each group starting with 54 rats) 
Table 2 
Effect of adriamycin on myocardial contents of mRNA and polyribosomes 
Animal group mRNA 
(pg/g heart) (%) 
Polyribosomes 
(rig/g heart) (70) 
Controls 21.3 f 4.5 (15) 100 752 + 84 (6) 100 
Adriamycin 
10 mg/kg b.w. 13.5 + 3.4 (8) 63.4 511 ?; 62(6) 68 
15 mg/kg b.w. 10.3 + 4.2 (6) 48.4 489 ? 106 (5) 65 
Values are the mean f SEM (no. preps.). In each preparation of mRNA, 10 pooled 
rat hearts were homogenized in 8 vol. buffer containing 10 mM Tris-HCI (pH 7.4), 
300 mM KCl, 5 mM MgCl,. 250 mM sucrose, 1% Triton X-100, 100 U/ml heparin. 
The postmitochondrial supernatant (PMS) was obtained by centrifugation 
(12 500 rev./mm, 20 min, 4°C) and used to isolate mRNA from the pelleted 
microsomes (42 000 rev./min, 70 min, 4’C in a Beckman Ti 60 rotor) by SDS- 
phenol extraction [27] and adsorption of the mRNA onto oligo(dT) cellulose 
[27]. The protein-synthesizing activity of the isolated, highly active mRNA was 
tested in the wheat germ system [ 281 and was generally of the order of 45 000 
cpm/pg mRNA using the conditions in [23]. For isolation of myocardial poly- 
ribosomes, 10 pooled rat hearts were homogenized in 8 vol. buffer containing 
10 mM Tris-HCl (pH 7.4). 250 mM KCI, 5 mM MgCl,, 250 mM sucrose, 1% 
Trrton X-100. The polyribosomes were isolated from the PMS essentially as 
described for rat liver [23,29] and were tested for protein-synthesizing activity in 
presence of pH 5 enzymes [23,29] 
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the my~ard~al mRNA content (table 2) from a value 
of 21.3 I.rg/g heart (controls) to 10.3 @g/g heart 
(15 mg adriamycinjkg b.w.), a decrease of -50%. On 
a per-heart-basis, the decrease of the myocardial 
mRNA content is with 65% even more pronounced 
(11.7 @g/heart in normal rats vs 4.1 ~g~heart in 
the adriamycin-treated rats; data calculated from 
tables 1,2). Similar sharp decreases are observed in 
the nlyocardial content of po~yr~bosomes after adria- 
mycin,treatment as shown in table 2, in accordance 
with [16,17]. 
The observation that adriamycin causes amuch 
greater decrease in myocardia1 mRNA content 
(table 2) than in myocardial total and microsomal 
RNA (table 1) suggests a predominant action of adria- 
mycin in the nucleus rather than in the nucleolus. 
Equal amounts of myocard~al mRNA from normal 
and adriamycin-treated rats (1.6 lttg each mRNA 
preparation) were then translated in vitro [18] and 
the cell-free synthesized products identified by SDS- 
slab-gel electrophoresis [ 191 and subsequent fluorog- 
raphy 1201. Fig.1 shows that the pattern of the cell- 
Fig.i . Translation of myocardial mRNA from normal (lane 3) 
and adriamycin-treated rats (lane 4) in the mRNA-dependent 
reticulocyte lysate system. Myocardial mRNA was isolated 
from normal and adr~myc~~reated rat heart muscle as in 
section 2 and [ 16,17j. Of each mRNA preparation 1.6 ~g was 
translated in the mRNAdependent reticulocyte lysate system 
[ 181. The cell-free synthesized products were separated on a 
10% SDS-polyacrylamide slab-gel (180 V, 4.5 h) [ 17,191 
and were visualized by ffuorography [ 17,20]. Lane (1) con- 
tained the indicated radioactive&‘, standards; (2) the reticu- 
locyte lysate without exogenous mRNA (12 230 cpm); (3) 
with myocardial mRNA from normal rats (50 120 cpm); (4) 
with myocardial mRNA from adriamycin-treated rats (49 430 
cpm). tn each case, the radioactivity was contained in 1 ~1 of 
a 25 &I reaction mixture. RL-protein+ refers to a protein syn- 
thesized in the reticulocyte lysate also in absence of mRNA. 
free synthesized myo~ardial proteins is practically 
identical for the two mRNA preparations, both quali- 
tatively and quantitatively (fig-l, runs 3,4). This 
implies that the two mRNA preparations must have a 
nearly identical composition with respect o the indi- 
vidual mRNA molecules coding for those specific 
proteins. Thus, in the adriamycin-treated hearts, ail 
mRNA species eem to be affected to a similar degree. 
By comparison with the indicated radioactive .Mr 
standards and with non-radioactive actin, myosin, 
tropomyosin, troponin and myogiobin, the cell-free 
synthesized proteins were identified as actin, tropo- 
nin-T, tropomyosin, 21 -myosin, L2-myosin, and 
myoglobin. Various minor radioactivity bands have 
as yet not been identified and represent other cell- 
free synthesized myocardial proteins. 
In [ 1.51 areduced myocardial protein synthesis 
rate was demonstrated in adriamycin-treated rats. Our 
findings of severely decreased contents of myocardial 
mRNA and polyribosomes suggest that this might be 
2 4 6 8 10 
pH 5 enzymes (p1 /assay) 
Fig.2. Effect of adriamyc~ on the activity of myocardiaf 
pH 5 enzymes. Myocardial pH 5 enzymes were isolated from 
the hearts of either normal (0) or adriamycin-treated animals 
(o), as described for isolationof rat liver (pl+ 5)enzymes 1241. 
Adriamycin-treatment of the animals was 10 mg/kg body wt, 
i.p., 2 weeks before decapitation. The activity of the pH 5 
enzymes was assayed in vitro in presence of myocardial poly- 
ribosomcs as in [24]. 
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one major factor for the reduction of myocardial 
protein synthesis after adriamycin treatment. In addi- 
tion, our results about an impairment of the activity 
of the myocardial pH 5 enzymes in adriamycin- 
treated rats (fig.2) suggest hat this could also con- 
tribute to the reduced myocardial protein synthesis 
rates in such animals [ 151. 
We conclude that the adriamycin caused decreases 
of the myocardial mRNA and polyribosome contents 
and the impairment of the activity of the myocardial 
pH 5 enzymes are the cause of the observed decrease 
in myocardial protein synthesis rates after treatment 
with adriamycin. This could be a major factor in the 
development of the adriamycin cardiomyopathy. Our 
results furthermore show that adriamycin causes an 
unselective decrease of all individual mRNA species 
coding for the major myofibrillar proteins which 
could suggest hat the primary action of adriamycin 
on the DNA is similarly unselective. 
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